NeoLNP?, the next-generation transfection kit (siRNA universal type), built on our advanced core technology for LNP. This kit offers:

• Advanced Ethanol-Free Transfection Vector: Our NeoLNP? kit built upon the i-Core LNP platform surpasses traditional cationic liposome transfection reagents and sets a new standard in the field of biodegradable ionizable lipid materials. The kit exhibits rapid metabolization in cells with minimal impact on cellular function and showing robustness under varying cell culture conditions, making it suitable for a wide array of cell types.
• Ease of Use: Encapsulation is carried out within one minute by simply mixing a small amount of sample with NeoLNP?. No need for any type of special equipment.
• Outstanding Delivery Performance: With NeoLNP? you can easily achieve a transfection rate of over 90%, ensuring the efficient delivery of your siRNA.
• Excellent Safety and Minimal Cytotoxicity:NeoLNP? is safe for in vitro applications, the cells maintain their viability and health, owing to its negligible cytotoxicity.
• Powerful Gene Silencing Effect: NeoLNP? enables siRNA with more potent inhibition of gene expression.

Efficient Cell Delivery Performance

Comparison between NeoLNP? siRNA transfection reagent and Lipofectamine 2000 for the delivery of 20 picomole (pmol) of Cy3-labeled siRNA into HEK293T, MCF7, and TWO3 cells cultivated within 96-well plates. At 6 hours post transfection, the cell culture medium was replaced, and cells were examined by fluorescence microscopy. The results distinctly showed the superior transfection efficiency of NeoLNP? over Lipofectamine 2000 across all the three cell types used.

“Zero” Stress on Cells: Very Low Cytotoxicity

HEK293T cells were introduced into 96-well plates and subjected to transfection of 1 pmol of siRNA by using NeoLNP? siRNA transfection reagent, Lipofectamine 2000 and Lipofectamine 3000, respectively. Control groups included a diluent and a negative control. 24 hours post transfection, the cell viability was assessed using the CCK-8 assay. According to the results, the diluent did not show any cytotoxic effect. NeoLNP? was found to be gentler and less cytotoxic in comparison with Lipofectamine 2000 and Lipofectamine 3000.

Using NeoLNP?, 5 pmol of siRNA was reverse-transfected into A549, Capan-2, and HFL-1 cells in a 96-well plate. At 24 hours post transfection, microscopic monitoring revealed clear and uniform cell edges with no obvious shrinkage or rounding of dead cells. The cells exhibited a healthy state, further affirming the remarkably low cytotoxicity of NeoLNP?.

Application Scenarios